Scott Okuno, MD
Enriched profileProfessor of Oncology, Mayo Clinic College of Medicine and Science; Chief Medical Officer, SARC (Sarcoma Alliance for Research through Collaboration) · Mayo Clinic
Scott Okuno is Professor of Oncology, Mayo Clinic College of Medicine and Science; Chief Medical Officer, SARC (Sarcoma Alliance for Research through Collaboration) at Mayo Clinic. OpenAlex indexes 291 publications with 12,654 citations (h-index 52); ClinicalTrials.gov lists 13 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Scott H. Okuno, MD, is Professor of Oncology, Mayo Clinic College of Medicine and Science. The public record shows 291 publications with 12,654 citations (h-index 52), centered on Colorectal Cancer, Breast Cancer, Prostate Cancer. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 8 companies, 1 NIH-funded awards (2009–2013).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Colorectal Cancer
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 17 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
- A Study of Effect of Megakaryocytes and Platelets in Breast Cancer
Sponsor: Mayo Clinic
- Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)
Sponsor: Philogen S.p.A.
Industry payments
Updated 27 Aug 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Deciphera Pharmaceuticals Inc.Program year20255 payments
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202412 payments$15,502openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
69.9%PD-1 inhibitor30.5%Pembrolizumab100%Part B, office-administered≥19 patientsMicrotubule Inhibitor21.8%Paclitaxel100%Part B, office-administered≥14 patientsMetabolism & gastrointestinal
25.7%Other antiemetics20.8%Fosaprepitant100%Part B, office-administered≥20 patientsSerotonin-3 Receptor Antagonist4.6%Palonosetron hcl52%Ondansetron hydrochloride43%Ondansetron Hcl6%Part D + Part B≥33 patientsSensory organs
3.6%Corticosteroid3.6%Dexamethasone sodium phosphate92%Dexamethasone8%Part D + Part B≥45 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2009–2013 per NIH RePORTER. The latest:
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.
Journal of clinical oncology
Clinical Trial2026 - A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma.
Clinical cancer research
Clinical Trial2025
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/scott-okuno-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Scott-H-Okuno-39072017
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Apple Podcasts
podcasts.apple.com/us/podcast/sarc-talk/id1655201709
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com ↗ - Spotify
open.spotify.com/show/0Q6Ms5290RQ41u052sr3Kc
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →open.spotify.com ↗ - X / Twitter
x.com/Liferaftgroup/status/1808535892627443767
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniassociation.mayo.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniassociation.mayo.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
- Board Certified
Medical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗ - Board Certified
Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗ - Board Certified
Hematology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Editorial & leadership roles
journal and society appointments- Chief Medical Officer
SARC (Sarcoma Alliance for Research through Collaboration), appointed September 2022; SARC Medical Officer since 2012; SARC Board of Directors member since October 2022
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sarctrials.org ↗ - Chair
Department of Hematology/Oncology, Mayo Clinic Health System
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →reininsarcoma.org ↗ - Co-chair
Sarcoma Subcommittee, NRG Oncology sarcoma working group
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →reininsarcoma.org ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayoclinic.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniassociation.mayo.edu ↗
- Chair
Mayo Clinic Health System Cancer Coordinating Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniassociation.mayo.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sarctrials.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Rick Nishimura, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic